Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Total Current Assets
All assets expected to be converted to cash or used up within one year.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 1078.7% from a year ago
Total current assets stood at $5.79M at the end of Q1 FY2026, up 1078.7% from a year earlier and down 21.1% from the prior quarter. Over 3 fiscal years it compounded at +432.1% a year.
Context
- Total current assets amounted to 100.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +1078.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.34M USD
- Year-over-year change
- +454.5%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.34M | +454.5% |
| FY2024 | 2024-12-31 | 1.32M | +204.2% |
| FY2023 | 2023-12-31 | 435.23K | +793.1% |
| FY2022 | 2022-12-31 | 48.73K | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Current Assets vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 total current assets of $5.79M is the lowest of the 6 companies compared; the peer median is $62.28M.
- Its year-over-year change of +1078.7% is the highest of 6, against a peer median of +8.9%.
- Total current assets amounts to 100.0% of total assets for TELO, versus a peer median of 88.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $139.04M | -18.0% | -27.7% | 42.6% | |
| Mar 2026 | $126.33M | +5.1% | -33.5% | 96.1% | |
| Mar 2026 | $62.28M | +284.0% | -26.7% | 98.7% | |
| Mar 2026 | $22.82M | +8.9% | -22.7% | 88.4% | |
| Mar 2026 | $5.91M | +27.0% | +23.1% | 29.9% | |
| Mar 2026 | $5.79M | +1078.7% | +432.1% | 100.0% | |
| Peer median (excluding TELO) | $62.28M | +8.9% | -26.7% | 88.4% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.